How Roche Is Positioned after 3Q17

1 2 3 4 5 6 7 8
How Roche Is Positioned after 3Q17 PART 1 OF 8

A Look at Roche’s New Drug Ocrevus in 3Q17

Roche’s revenue trends

In 3Q17, Roche Holding (RHHBY) generated revenues of 13.1 billion Swiss francs, which was a ~5% rise YoY (year-over-year). Its Pharmaceuticals segment generated revenues of 10.1 billion Swiss francs, which reflected a ~4% rise YoY. Its Diagnostics segment generated revenues of 3.0 billion Swiss francs, which was a ~6% rise YoY.

In 3Q17, the United States, Europe, and Japan contributed 5.1 billion Swiss francs, 2.2 billion Swiss francs, and 904 million Swiss francs, respectively, to Roche’s net Pharmaceuticals revenues. That reflected a rise of ~11% rise, a fall of ~2%, and a fall of ~3%, respectively, YoY. Ocrevus, Tecentriq, and Perjeta primarily affected revenue growth for the Pharmaceuticals segment in 3Q17.

A Look at Roche&#8217;s New Drug Ocrevus in 3Q17

Interested in BIIB? Don't miss the next report.

Receive e-mail alerts for new research on BIIB

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Ocrevus: Revenue trends

In March 2017, the FDA (U.S. Food & Drug Administration) approved Roche’s Ocrevus for the treatment of patients with active relapsing multiple sclerosis (or RMS) and primary progressive multiple sclerosis (or PPMS). In 3Q17, Ocrevus generated revenues of 308 million Swiss francs compared to 308 million Swiss francs in 2Q17. In 3Q17, Ocrevus witnessed a ~60% growth on a QoQ (quarter-over-quarter) basis. In the US market, Ocrevus generated revenues of 306 million Swiss francs.

In September 2017, the Swiss agency for the authorization and supervision of therapeutic products (or Swissmedic) approved Ocrevus for the treatment of adult individuals with RMS and PPMS. Ocrevus is the first drug approved in Switzerland for the treatment of PPMS. Ocrevus competes with Sanofi’s (SNY) Aubagio, Biogen’s (BIIB) Fampyra and Tysabri, Novartis’s (NVS) Gilenya, and Teva Pharmaceutical’s Copaxone in the MS (multiple sclerosis) drug market. The recent regulatory approval is expected to boost revenue growth for Ocrevus.

Roche’s revenue growth could boost the share price of the Vanguard International Dividend Appreciation Index ETF (VIGI). Roche makes up 2.8% of VIGI’s total portfolio holdings.


Please select a profession that best describes you: